(Q42050352)

15 October 2017

title

HIV-1 Vpr increases HCV replication through VprBP in cell culture (English)

1 reference

15 October 2017

Yanling Yan

1

1 reference

15 October 2017

Fang Huang

2

1 reference

15 October 2017

Ting Yuan

3

1 reference

15 October 2017

Binlian Sun

4

1 reference

15 October 2017

Rongge Yang

5

1 reference

15 October 2017

publication date

23 July 2016

1 reference

15 October 2017

1 reference

15 October 2017

volume

223

1 reference

15 October 2017

page(s)

153-160

1 reference

Epidemiology of viral hepatitis and HIV co-infection

15 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.07.007

The DNA damage sensors ataxia-telangiectasia mutated kinase and checkpoint kinase 2 are required for hepatitis C virus RNA replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.07.007

HIV-1 Vpr-mediated G2 arrest involves the DDB1-CUL4AVPRBP E3 ubiquitin ligase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.07.007

Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.07.007

HIV-1 Nef is transferred from expressing T cells to hepatocytic cells through conduits and enhances HCV replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.07.007

(-)-Epigallocatechin-3-gallate inhibits the replication cycle of hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.07.007

DNA methyltransferases 1 and 3B are required for hepatitis C virus infection in cell culture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.07.007

Vpr Promotes Macrophage-Dependent HIV-1 Infection of CD4+ T Lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.07.007

Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.07.007

HIV-1 Vpr activates the G2 checkpoint through manipulation of the ubiquitin proteasome system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.07.007

Human immunodeficiency virus type 1 Vpr increases hepatitis C virus RNA replication in cell culture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.07.007

HIV-1 Vpr-a still "enigmatic multitasker".

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.07.007

Compensatory mutations in NS3 and NS5A proteins enhance the virus production capability of hepatitis C reporter virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.07.007

The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.07.007

Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.07.007

Inhibition of CUL4A Neddylation causes a reversible block to SAMHD1-mediated restriction of HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.07.007

Vpr in plasma of HIV type 1-positive patients is correlated with the HIV type 1 RNA titers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.07.007

HIV-1 Vpr induces TLR4/MyD88-mediated IL-6 production and reactivates viral production from latency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.07.007

Immunohistochemical evidence for human immunodeficiency virus-1 infection of liver Kupffer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.07.007

Lentiviral Vpr usurps Cul4-DDB1[VprBP] E3 ubiquitin ligase to modulate cell cycle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.07.007

Characterization of TRIM62 as a RING finger E3 ubiquitin ligase and its subcellular localization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.07.007

Identification of three interferon-inducible cellular enzymes that inhibit the replication of hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.07.007

Cell culture and infection system for hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.07.007

HIV, age, and the severity of hepatitis C virus-related liver disease: a cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.07.007

DNA damage enhances integration of HIV-1 into macrophages by overcoming integrase inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.07.007

The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in U.S. veterans with hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.07.007

The natural history of liver cirrhosis in HIV-hepatitis C virus-coinfected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.07.007

Premature activation of the SLX4 complex by Vpr promotes G2/M arrest and escape from innate immune sensing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.07.007

HIV1 Vpr arrests the cell cycle by recruiting DCAF1/VprBP, a receptor of the Cul4-DDB1 ubiquitin ligase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.07.007

Serum Vpr regulates productive infection and latency of human immunodeficiency virus type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.07.007

HIV increases HCV replication in a TGF-beta1-dependent manner.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.07.007

Vpr R77Q is associated with long-term nonprogressive HIV infection and impaired induction of apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.07.007

The interaction of vpr with uracil DNA glycosylase modulates the human immunodeficiency virus type 1 In vivo mutation rate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.07.007

Vpr overcomes macrophage-specific restriction of HIV-1 Env expression and virion production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.07.007

Identification of type I and type II interferon-induced effectors controlling hepatitis C virus replication.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.07.007

HIV-1 Vpr induces apoptosis through caspase 9 in T cells and peripheral blood mononuclear cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.07.007

Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.07.007

VprBP (DCAF1): a promiscuous substrate recognition subunit that incorporates into both RING-family CRL4 and HECT-family EDD/UBR5 E3 ubiquitin ligases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.07.007

HIV-1 Vpr induces ATM-dependent cellular signal with enhanced homologous recombination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.07.007

HIV relies on neddylation for ubiquitin ligase-mediated functions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.07.007

HIV-1 Vpr: a closer look at the multifunctional protein from the structural perspective.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.07.007

HIV Vpr protein upregulates microRNA-122 expression and stimulates hepatitis C virus replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.07.007

Human immunodeficiency virus-1 Rev protein activates hepatitis C virus gene expression by directly targeting the HCV 5'-untranslated region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.07.007

The Tat protein of human immunodeficiency virus-1 enhances hepatitis C virus replication through interferon gamma-inducible protein-10.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.07.007

Activation of the ATR-mediated DNA damage response by the HIV-1 viral protein R.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.07.007

Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.07.007

An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.07.007

Human immunodeficiency virus type 1 Vpr is a positive regulator of viral transcription and infectivity in primary human macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.07.007

DDB1 and Cul4A are required for human immunodeficiency virus type 1 Vpr-induced G2 arrest

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.07.007

Interaction of Virion Protein Vpr of Human Immunodeficiency Virus Type 1 with Cellular Transcription Factor Sp1 and trans-Activation of Viral Long Terminal Repeat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.07.007

The HIV1 protein Vpr acts to promote G2 cell cycle arrest by engaging a DDB1 and Cullin4A-containing ubiquitin ligase complex using VprBP/DCAF1 as an adaptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.07.007

Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.07.007

HIV-1 Vpr induces interferon-stimulated genes in human monocyte-derived macrophages.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.07.007

Robust hepatitis C virus infection in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.07.007

The HIV-1 accessory protein Vpr induces the degradation of the anti-HIV-1 agent APOBEC3G through a VprBP-mediated proteasomal pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.07.007

Human immunodeficiency virus type 1 Vpr arrests the cell cycle in G2 by inhibiting the activation of p34cdc2-cyclin B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.07.007

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VIRUSRES.2016.07.007

1 reference

15 October 2017

1 reference